Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology Supplement 1/13 Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology Frühjahrstagung 2013 der Österreichischen Gesellschaft für Hämatologie und Onkologie und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich (AHOP) Linz, 18.–20. April 2013 President : Univ.-Prof. Dr. Peter Bettelheim Secretary: OA Univ.-Doz. Dr. Karl J. Aichberger 1. Interne Abteilung Krankenhaus der Elisabethinen Linz, Austria memo · Vol. 6 · Suppl 1/13 © Springer-Verlag Wien 1 Published online: 3 April 2013 Supplement 1/13 2 Suppl 1/13 1 3 Abstracts Background: The combination of chemotherapy and anti-EGFR Young Investigators Oral monoclonal antibodies has proven clinical efficacy in NSCLC. Recent reports emphasize the important role of increased Treg lev- Presentations els for tumor immune escape in epithelial malignancies. The aim of the current study is to determine the role of Treg levels for thera- peutic response and the impact of neoadjuvant chemo-immuno- A01 therapy on the Treg compartment. Methods: We first analyzed in-vitro the effects of Treg on natu- ral killer cell-mediated cetuximab-antibody dependent cellular The impact of miR-155 on cytokine cytoxicity. 31 patients suffering from NSCLC were included in a regulation and tumor growth in neoadjuvant study protocol and received two cycles of chemo- immunotherapy (Cetuximab+Docetaxel+Cisplatin) prior to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology

memo - Magazine of European Medical Oncology , Volume 6 (1) – Apr 3, 2013

Loading next page...
 
/lp/springer-journals/proceedings-of-the-annual-meeting-of-the-austrian-society-of-M6Ku5IGARk

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0079-7
Publisher site
See Article on Publisher Site

Abstract

Supplement 1/13 Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology Frühjahrstagung 2013 der Österreichischen Gesellschaft für Hämatologie und Onkologie und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich (AHOP) Linz, 18.–20. April 2013 President : Univ.-Prof. Dr. Peter Bettelheim Secretary: OA Univ.-Doz. Dr. Karl J. Aichberger 1. Interne Abteilung Krankenhaus der Elisabethinen Linz, Austria memo · Vol. 6 · Suppl 1/13 © Springer-Verlag Wien 1 Published online: 3 April 2013 Supplement 1/13 2 Suppl 1/13 1 3 Abstracts Background: The combination of chemotherapy and anti-EGFR Young Investigators Oral monoclonal antibodies has proven clinical efficacy in NSCLC. Recent reports emphasize the important role of increased Treg lev- Presentations els for tumor immune escape in epithelial malignancies. The aim of the current study is to determine the role of Treg levels for thera- peutic response and the impact of neoadjuvant chemo-immuno- A01 therapy on the Treg compartment. Methods: We first analyzed in-vitro the effects of Treg on natu- ral killer cell-mediated cetuximab-antibody dependent cellular The impact of miR-155 on cytokine cytoxicity. 31 patients suffering from NSCLC were included in a regulation and tumor growth in neoadjuvant study protocol and received two cycles of chemo- immunotherapy (Cetuximab+Docetaxel+Cisplatin) prior to

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Apr 3, 2013

There are no references for this article.